Etoposide et risque leucémogène = Etoposide leukemogenicityGUENFOUDI-ROULLAUD, M. P; MENAT, C; GIRARD, F et al.Journal de pharmacie clinique (Paris). 1998, Vol 17, Num 2, pp 71-73, issn 0291-1981Article

Etoposide for the treatment of paediatric tumours : What is the best way to give it ?LOWIS, S. P; NEWELL, D. R.European journal of cancer (1990). 1996, Vol 32, Num 13, pp 2291-2297, issn 0959-8049Article

Précision des préparations à base de cytostatiques : étude réalisée sur 3 unités centralisées de reconstitution = Precision of the cytotoxics preparations : study realized on 3 cytotoxics drug preparation unitGIRARD, F; MENAT, C; GUENFOUDI, M.-P et al.Journal de pharmacie clinique (Paris). 1999, Vol 18, Num 1, pp 62-63, issn 0291-1981Conference Paper

Low-dose oral etoposide monotherapy in adult Langerhans cell histiocytosisHELMBOLD, P; HEGEMANN, B; HOLZHAUSEN, H.-J et al.Archives of dermatology (1960). 1998, Vol 134, Num 10, pp 1275-1278, issn 0003-987XArticle

Chromosomal aberrations induced by 5-azacytidine combined with VP-16 (etoposide) in CHO-K1 and XRS-5 cell linesGUIMARAES, A. P. A; DIAS, F. L; CARDOSO, R. S et al.Teratogenesis, carcinogenesis, and mutagenesis. 2003, pp 171-186, issn 0270-3211, 16 p., SUP1Article

A randomized trial of treatment for multisystem Langerhans' cell histiocytosisGADNER, Helmut; GROIS, Nicole; PRITCHARD, Jon et al.The Journal of pediatrics. 2001, Vol 138, Num 5, pp 728-734, issn 0022-3476Article

Chromosome aberrations after etoposide containing cisplatin-based chemotherapy for malignant germ-cell tumoursHERNANDEZ, A. M; FOSSA, S. D; BRØGGER, A et al.Annals of oncology. 2000, Vol 11, Num 7, pp 897-898, issn 0923-7534Article

Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administrationNAGAO, T; YOSHIMURA, S; SAITO, Y et al.Teratogenesis, carcinogenesis, and mutagenesis. 1999, Vol 19, Num 3, pp 233-241, issn 0270-3211Article

Lignans from the seeds of Hernandia sonoraUDINO, L; ABAUL, J; BOURGEOIS, P et al.Planta medica. 1999, Vol 65, Num 3, pp 279-281, issn 0032-0943Article

Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxinsSMITH, M. A; RUBINSTEIN, L; MISER, J et al.Journal of clinical oncology. 1999, Vol 17, Num 2, pp 569-577, issn 0732-183XArticle

The mechanism of photo-ionization of podophyllotoxin and its derivatives : a laser flash photolysis studyWANG, S.-L; YAO, S.-D; WANG MEI et al.Radiation physics and chemistry (1993). 1998, Vol 53, Num 6, pp 623-628, issn 0969-806XArticle

A novel enzymatic dehydrogenation of podophyllotoxin congeners by yeast cellsKAMAL, A; DAMAYANTHI, Y.Bioorganic & medicinal chemistry letters (Print). 1997, Vol 7, Num 6, pp 657-662, issn 0960-894XArticle

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposideTOFFOLI, G; SORIO, R; GIGANTE, M et al.British journal of cancer. 1997, Vol 75, Num 5, pp 715-721, issn 0007-0920Article

Design and Effective Synthesis of the First 4-Aza-2,3-didehydropodophyllotoxin Rigid Aminologue : A N-Methyl-4-[(3,4,5-trimethoxyphenyl)amino]-1,2-dihydroquinoline-lactoneLABRUERE, Raphaël; HELISSEY, Philippe; DESBENE-FINCK, Stéphanie et al.Journal of organic chemistry. 2008, Vol 73, Num 9, pp 3642-3645, issn 0022-3263, 4 p.Article

PAP modulations in Daudi cells and Molt-3 cells treated with etoposide are mutually associated with morphological evidence of apoptosisTHOMADAKI, E; HAVREDAKI, M; TSIAPALIS, C. M et al.The International journal of biological markers. 2004, Vol 19, Num 3, pp 203-212, issn 0393-6155, 10 p.Article

Etoposide: Discovery and medicinal chemistryMERESSE, Philippe; DECHAUX, Elsa; MONNERET, Claude et al.Current medicinal chemistry. 2004, Vol 11, Num 18, pp 2443-2466, issn 0929-8673, 24 p.Article

Podophyllotoxin: distribution, sources, applications and new cytotoxic derivativesGORDALIZA, M; GARCIA, P. A; DEL CORRAL, J. M et al.Toxicon (Oxford). 2004, Vol 44, Num 4, pp 441-459, issn 0041-0101, 19 p.Article

Antitumor properties of podophyllotoxin and related compoundsM.GORDALIZA; CASTRO, M. A; DEL CORRAL, J. M et al.Current pharmaceutical design. 2000, Vol 6, Num 18, pp 1811-1839, issn 1381-6128Article

Accumulation of podophyllotoxin and related lignans in cell suspension cultures of Linum albumSMOLLNY, T; WICHERS, H; KALENBERG, S et al.Phytochemistry. 1998, Vol 48, Num 6, pp 975-979, issn 0031-9422Article

Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site : A Hellenic co-operative Oncology Group phase II studyBRIASOULIS, E; TSAVARIS, N; FOUNTZILAS, G et al.Oncology. 1998, Vol 55, Num 5, pp 426-430, issn 0030-2414Article

Etoposide : Four decades of development of a topoisomerase II inhibitorHANDE, K. R.European journal of cancer (1990). 1998, Vol 34, Num 10, pp 1514-1521, issn 0959-8049Conference Paper

Chemotherapeutic targeting of etoposide to various tissues on the basis of polyamine levelWATANABE, Satoru; SATO, Shoichi; NAGASE, Sumika et al.Journal of drug targeting. 2004, Vol 12, Num 1, pp 57-62, issn 1061-186X, 6 p.Article

Pharmacokinetic optimisation of treatment with oral etoposideTOFFIOLI, Giuseppe; CORONA, Giuseppe; BASSO, Barbara et al.Clinical pharmacokinetics. 2004, Vol 43, Num 7, pp 441-466, issn 0312-5963, 26 p.Article

Class I histiocytosis : Response to combination of etoposide and prednisoloneDATTA, V; MISHRA, O. P; DAS, B. K et al.Indian pediatrics. 1999, Vol 36, Num 1, pp 83-86, issn 0019-6061Article

Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cellsSAKAMOTO, H; HARA, H; HIRANO, K et al.Cancer letters. 1999, Vol 135, Num 1, pp 113-119, issn 0304-3835Article